AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

Rhea-AI Summary

AIM ImmunoTech Inc. (NYSE: American AIM) announced a live video webcast presentation on January 26, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO Thomas K. Equels will present the company’s advancements in therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. The event will feature a corporate presentation followed by an interactive Q&A session. Interested parties may submit questions live or in advance. The presentation will be accessible via the company's website, with a replay available for one year.

Live video webcast presentation on Wednesday, January 26th at 10:00 AM ET

OCALA, Fla., Jan. 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 10:00 AM ET.

As part of the virtual event, the Company will provide a corporate presentation, followed by a moderated interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

For more information, please visit www.aimimmuno.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
AIM@jtcir.com

FAQ

What is the date and time of AIM ImmunoTech's presentation?

AIM ImmunoTech is presenting on January 26, 2022, at 10:00 AM ET.

Who is presenting for AIM ImmunoTech at the conference?

CEO Thomas K. Equels will present for AIM ImmunoTech at the conference.

What conference is AIM ImmunoTech participating in?

AIM ImmunoTech is participating in the Virtual Investor 2022 Top Picks Conference.

How can I access the AIM ImmunoTech presentation live?

The presentation can be accessed via a live video webcast on AIM ImmunoTech's website.

Will there be a Q&A session during the AIM ImmunoTech presentation?

Yes, there will be a moderated interactive Q&A session following the corporate presentation.

How long will the webcast replay of AIM ImmunoTech’s presentation be available?

The webcast replay will be available for one year after the live presentation.